Weight-Loss drug trial aims to tame hidden inflammation in HIV
NCT ID NCT06935838
Summary
This study is testing if a medication called tirzepatide, which is approved for weight loss and diabetes, can also help reduce chronic inflammation in people living with HIV who are overweight or obese. It will involve 12 adults with well-controlled HIV who will receive weekly injections of the drug for 12 weeks. Researchers will measure changes in body weight, body fat, liver health, and specific markers of inflammation in the blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY AND OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
John A Burns School of Medicine
RECRUITINGHonolulu, Hawaii, 96813, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.